menu
    • menu
    [{"orgOrder":0,"company":"RDC Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Inapplicable"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Circadian Wellness Corp","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Circadian Wellness Sleep SL","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Circadian Wellness Corp","highestDevelopmentStatusID":"1","companyTruncated":"TruDiagnostic \/ Circadian Wellness Corp"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Enalare Therapeutics"},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AEX-2","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aexon Labs \/ NLS Pharmaceutics","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AEX-2","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danavorexton","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Danavorexton","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nyree Penn","sponsor":"Masimo | PROSOMNIA Sleep Health & Wellness","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Sleep","graph2":"Phase I","graph3":"Nyree Penn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nyree Penn \/ Masimo | PROSOMNIA Sleep Health & Wellness","highestDevelopmentStatusID":"6","companyTruncated":"Nyree Penn \/ Masimo | PROSOMNIA Sleep Health & Wellness"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0.44,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.44,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Heptares \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Holling Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Holling Bio-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Holling Bio-Pharma"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"MDbio Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabis Sativa Oil","moa":"||Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"MDbio Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MDbio Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MDbio Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Apotex Inc"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Neuraxpharm"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Triazolam","moa":"GABA-A receptor; anion channel","graph1":"Sleep","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"||Phosphate","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Phosphate","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Phosphate","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcium","moa":"||Phosphate","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Monteloeder","sponsor":"Suanfarma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Acquisition","leadProduct":"Lemon Verbena Extract","moa":"GABAA receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Monteloeder","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Monteloeder \/ Suanfarma","highestDevelopmentStatusID":"15","companyTruncated":"Monteloeder \/ Suanfarma"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Divestment","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"RareStone Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Inapplicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioprojet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Citrine Medicine"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioprojet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Chloral Hydrate","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanovia \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Inapplicable"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chloral Hydrate","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanovia \/ Lindus Health","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Lindus Health"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JZP258","moa":"Oxybate receptors (GABA-B)","graph1":"Sleep","graph2":"Phase IV","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Charles A. Czeisler","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Charles A. Czeisler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charles A. Czeisler \/ Axsome Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Charles A. Czeisler \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Pennsylvania \/ Axsome Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Axsome Therapeutics"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Eisai | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California, San Francisco \/ Eisai | Stanford University","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Eisai | Stanford University"},{"orgOrder":0,"company":"Columbia University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Columbia University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Merck & Co"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avecho","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avecho \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Inapplicable"},{"orgOrder":0,"company":"Avecho","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Avecho \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Sandoz B2B"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.13,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.080000000000000002,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ RTW Investments"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.63,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.63,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0.63,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citrine Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Citrine Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Citrine Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citrine Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nanjing Chia-tai Tianqing Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Nanjing Chia-tai Tianqing Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing Chia-tai Tianqing Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP1R","graph1":"Sleep","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"||Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"A. Vogel","sponsor":"DCC Convex","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Eschscholzia Californica Herba","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"A. Vogel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"A. Vogel \/ DCC Convex","highestDevelopmentStatusID":"10","companyTruncated":"A. Vogel \/ DCC Convex"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"FT218","moa":"GABA-A receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NLS-2","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FT218","moa":"GABA-A receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aculys Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IHL-42X","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Raphael Heinzer","sponsor":"Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AD128","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Raphael Heinzer","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Raphael Heinzer \/ Apnimed","highestDevelopmentStatusID":"9","companyTruncated":"Raphael Heinzer \/ Apnimed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"||SLC6A2","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV | Carbonic anhydrase I","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Penn State University","sponsor":"University of Arizona | Proactive Life Inc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Cbti","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Penn State University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Penn State University \/ University of Arizona | Proactive Life Inc","highestDevelopmentStatusID":"9","companyTruncated":"Penn State University \/ University of Arizona | Proactive Life Inc"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ALKS2680","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD036","moa":"GPR119","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taisho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Samelisant","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Apnimed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Apnimed"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Defined Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Defined Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Defined Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Defined Research \/ Inapplicable"},{"orgOrder":0,"company":"Bod Australia","sponsor":"Woolcock Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Bod Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bod Australia \/ Woolcock Institute of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Bod Australia \/ Woolcock Institute of Medical Research"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Stanford University","sponsor":"Avadel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Stanford University \/ Avadel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Avadel Pharmaceuticals"},{"orgOrder":0,"company":"KemPharm","sponsor":"Hypersomnia Foundation","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Hypersomnia Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Hypersomnia Foundation"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"RARE-X","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ RARE-X","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ RARE-X"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ BVF Partners"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ BVF Partners"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Laidlaw & Company","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Laidlaw & Company"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Adare Pharma Solutions \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Pharma Solutions \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ ResolutionRx"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ University Of Illinois Chicago","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"Istituto Auxologico Italiano","sponsor":"YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AD128","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Istituto Auxologico Italiano","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Istituto Auxologico Italiano \/ YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Istituto Auxologico Italiano \/ YGHEA, CRO Division of Ecol Studio spa | STM Pharma PRO srl | Apnimed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Serdexmethylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zevra Therapeutics \/ Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Rho Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TAK-861","moa":"Orexin receptor type 2 (HCRTR2)","graph1":"Sleep","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"Neurokinin 1 receptor | Neurokinin 3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AD109","moa":"M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"CYP11B2","graph1":"Sleep","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Reboxetine Mesylate","moa":"SLC6A2","graph1":"Sleep","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Axsome Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV | Carbonic anhydrase I","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sivopixant","moa":"||P2RX3","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Heel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Avena Sativa","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heel \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD182","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD113","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-360","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-360","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Alpha Wave Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"||Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Morningside Ventures"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD313","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10506","moa":"Unknown","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Sosei Group Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MK-6552","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IHL-42X","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HEC83518","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunshine Lake Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HEC83518","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunshine Lake Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase I","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Brigham and Women's Hospital \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Brigham and Women's Hospital \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"E2086","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JZP441","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Jazz Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"OX2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":1.1399999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":1.1399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Fortrea","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Acetazolamide","moa":"||Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV | Carbonic anhydrase I","graph1":"Sleep","graph2":"Phase I","graph3":"Fortrea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fortrea \/ Incannex Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Fortrea \/ Incannex Healthcare"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV | Carbonic anhydrase I","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taisho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ORX142","moa":"Undisclosed","graph1":"Sleep","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"X-Chem","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X-Chem \/ Orexia Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ Orexia Therapeutics"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Samelisant","moa":"Histamine H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Zurich \/ Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Zurich \/ Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals"},{"orgOrder":0,"company":"Abyss Ingredients","sponsor":"Daacro","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fish Hydrolysate","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Abyss Ingredients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abyss Ingredients \/ Daacro","highestDevelopmentStatusID":"1","companyTruncated":"Abyss Ingredients \/ Daacro"},{"orgOrder":0,"company":"Asystem, Inc.","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"De-Stress Gummies","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Asystem, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Asystem, Inc. \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Asystem, Inc. \/ Citruslabs"},{"orgOrder":0,"company":"Uriach Consumer Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Aquilea Sueno Forte","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Uriach Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Uriach Consumer Healthcare \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Uriach Consumer Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Laboratoires Pronutri","sponsor":"Clin-Experts","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutri Pnea","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Laboratoires Pronutri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratoires Pronutri \/ Clin-Experts","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Pronutri \/ Clin-Experts"},{"orgOrder":0,"company":"Comercial Quimica Masso, S.A","sponsor":"Universit\u00e9 Catholique de Louvain","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Comercial Quimica Masso, S.A","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Comercial Quimica Masso, S.A \/ Universit\u00e9 Catholique de Louvain","highestDevelopmentStatusID":"1","companyTruncated":"Comercial Quimica Masso, S.A \/ Universit\u00e9 Catholique de Louvain"},{"orgOrder":0,"company":"National Yang Ming Chiao Tung University","sponsor":"Bened Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"PS128","moa":"Dopamine receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"National Yang Ming Chiao Tung University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Yang Ming Chiao Tung University \/ Bened Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"National Yang Ming Chiao Tung University \/ Bened Biomedical"},{"orgOrder":0,"company":"National Yang Ming Chiao Tung University","sponsor":"Bened Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"PS150","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"National Yang Ming Chiao Tung University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Yang Ming Chiao Tung University \/ Bened Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"National Yang Ming Chiao Tung University \/ Bened Biomedical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"EMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aytu BioScience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha-1\/beta-1\/gamma-2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cosette Pharma"},{"orgOrder":0,"company":"PAO Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAO Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PAO Group \/ Inapplicable"},{"orgOrder":0,"company":"Elixinol Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Elixinol Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Elixinol Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elixinol Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Entourage Health","sponsor":"Irwin Naturals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Gel","sponsorNew":"Entourage Health \/ Irwin Naturals","highestDevelopmentStatusID":"15","companyTruncated":"Entourage Health \/ Irwin Naturals"},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Kinderfarms","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinderfarms \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kinderfarms \/ Inapplicable"},{"orgOrder":0,"company":"Humanis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"TURKEY","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humanis \/ Inapplicable"},{"orgOrder":0,"company":"Kurume University","sponsor":"Eisai Inc | Mebix","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"Kurume University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurume University \/ Eisai Inc | Mebix","highestDevelopmentStatusID":"11","companyTruncated":"Kurume University \/ Eisai Inc | Mebix"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"VA Loma Linda Health Care System","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Sleep","graph2":"Phase IV","graph3":"VA Loma Linda Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Pill","sponsorNew":"VA Loma Linda Health Care System \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"VA Loma Linda Health Care System \/ Inapplicable"},{"orgOrder":0,"company":"Murdoch Childrens Research Institute","sponsor":"Monash Health | Royal Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Murdoch Childrens Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Murdoch Childrens Research Institute \/ Monash Health | Royal Children's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Murdoch Childrens Research Institute \/ Monash Health | Royal Children's Hospital"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Sao Paulo \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"University of Basel","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Valerian-Hop Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Zeller Soehne \/ University of Basel","highestDevelopmentStatusID":"11","companyTruncated":"Max Zeller Soehne \/ University of Basel"},{"orgOrder":0,"company":"Dominik Ettlin","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Sleep","graph2":"Phase IV","graph3":"Dominik Ettlin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dominik Ettlin \/ Merz Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Dominik Ettlin \/ Merz Pharma"},{"orgOrder":0,"company":"Ignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Ignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aroxybutynin","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"St. Joseph's Healthcare Hamilton \/ McMaster University"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Ab Initio Pharma","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Ab Initio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ab Initio Pharma \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"Ab Initio Pharma \/ ResolutionRx"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Sleep","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Sequential Medicine Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"Histamine H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Sequential Medicine Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequential Medicine Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sequential Medicine Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Good Ventures | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Good Ventures | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Good Ventures | Merck & Co"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Merck & Co"},{"orgOrder":0,"company":"Shionogi Apnimed Sleep Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sivopixant","moa":"P2RX3","graph1":"Sleep","graph2":"Phase II","graph3":"Shionogi Apnimed Sleep Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi Apnimed Sleep Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi Apnimed Sleep Science \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FINLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tasipimidine","moa":"Alpha-2A adrenergic receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orion Corporation \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Icon Plc"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD036","moa":"GPR119","graph1":"Sleep","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ Apnimed"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI 1467335","moa":"Sphingosine kinase 2","graph1":"Sleep","graph2":"Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntara Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syntara Limited \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"HVMN Inc | KETONE-IQ","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"1,3 Butanediol","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ","highestDevelopmentStatusID":"7","companyTruncated":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZLT-101","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zelira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Sleep","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"HVMN Inc | KETONE-IQ","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"1,3 Butanediol","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ","highestDevelopmentStatusID":"7","companyTruncated":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pharmavite \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ulotaront","moa":"Trace amine-associated receptor 1 | Serotonin 1a (5-HT1a) receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Northwell Health","sponsor":"National Library of Medicine | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ National Library of Medicine | Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ National Library of Medicine | Columbia University"},{"orgOrder":0,"company":"Flinders University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BAY2586116","moa":"TASK1\/TASK3","graph1":"Sleep","graph2":"Phase I","graph3":"Flinders University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Spray","sponsorNew":"Flinders University \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Flinders University \/ Bayer AG"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Beijing CTSmed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Beijing CTSmed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Beijing CTSmed"},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/ Panacea Venture"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"E2086","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"TPM-1116","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Bioprojet Pharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0.39000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Bioprojet Pharma \/ Harmony Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Bioprojet Pharma \/ Harmony Biosciences"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEX-41","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEX-41","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RO7117997","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ PsychoGenics"},{"orgOrder":0,"company":"Apnimed","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Shionogi","highestDevelopmentStatusID":"2","companyTruncated":"Apnimed \/ Shionogi"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":"2","companyTruncated":"McGill University \/ Brain Canada"},{"orgOrder":0,"company":"Laval University","sponsor":"Toronto Metropolitan University | The Royal Ottawa Mental Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laval University \/ Toronto Metropolitan University | The Royal Ottawa Mental Health Centre","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Toronto Metropolitan University | The Royal Ottawa Mental Health Centre"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Sonidor","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italfarmaco \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Italfarmaco \/ Tigermed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"ASPEN Rhoads Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ ASPEN Rhoads Research Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ ASPEN Rhoads Research Foundation"},{"orgOrder":0,"company":"4Life Research, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Sleep Supplement","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"4Life Research, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4Life Research, LLC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"4Life Research, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Radicle Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Inapplicable"},{"orgOrder":0,"company":"Radicle Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Sleep Study Product Usage","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Inapplicable"},{"orgOrder":0,"company":"Carlos O Mendivil","sponsor":"Team Foods Colombia S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Carlos O Mendivil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carlos O Mendivil \/ Team Foods Colombia S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Carlos O Mendivil \/ Team Foods Colombia S.A."},{"orgOrder":0,"company":"Radicle Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Inapplicable"},{"orgOrder":0,"company":"A. Vogel","sponsor":"Daacro GmbH & Co. KG | Biochemical Laboratory of the Department of Psychobiology, University of Trier | Synlab","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Sleep Well Sachet","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"A. Vogel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Sachet","sponsorNew":"A. Vogel \/ Daacro GmbH & Co. KG | Biochemical Laboratory of the Department of Psychobiology, University of Trier | Synlab","highestDevelopmentStatusID":"1","companyTruncated":"A. Vogel \/ Daacro GmbH & Co. KG | Biochemical Laboratory of the Department of Psychobiology, University of Trier | Synlab"},{"orgOrder":0,"company":"Radicle Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Inapplicable"},{"orgOrder":0,"company":"Danone Nutricia Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fortified Beverage","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Danone Nutricia Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Nutricia Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Danone Nutricia Research \/ Inapplicable"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Dermatology Consulting Services, High Point NC","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanex \/ Dermatology Consulting Services, High Point NC","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Dermatology Consulting Services, High Point NC"},{"orgOrder":0,"company":"Florida State University","sponsor":"Milk Specialties Global","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Casein","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Florida State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florida State University \/ Milk Specialties Global","highestDevelopmentStatusID":"1","companyTruncated":"Florida State University \/ Milk Specialties Global"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Adaptogen Elixir","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Radicle Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Radicle Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radicle Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Radicle Science \/ Inapplicable"},{"orgOrder":0,"company":"The Water Street Collective","sponsor":"British American Tobacco (Investments) Limited | HCD Research","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"The Water Street Collective","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Water Street Collective \/ British American Tobacco (Investments) Limited | HCD Research","highestDevelopmentStatusID":"1","companyTruncated":"The Water Street Collective \/ British American Tobacco (Investments) Limited | HCD Research"},{"orgOrder":0,"company":"Nutrition Institute, Slovenia","sponsor":"Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Nutrition Institute, Slovenia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition Institute, Slovenia \/ Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija","highestDevelopmentStatusID":"1","companyTruncated":"Nutrition Institute, Slovenia \/ Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija"},{"orgOrder":0,"company":"Efforia, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Moonbrew","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Efforia, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Efforia, Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Efforia, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Omega-3","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ Inapplicable"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"Gamma-aminobutyric acid receptor subunit gamma-2; Sodium- and chloride-dependent GABA transporter 3; Integrin alpha-4; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-5; Sodium- and chloride-dependent GABA transporter 1; Gamma-aminobutyric acid type B receptor subunit 1; Gamma-aminobutyric acid type B receptor subunit 2; Glycine amidinotransferase, mitochondrial","graph1":"Sleep","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Inapplicable"},{"orgOrder":0,"company":"Bettery S.A.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Melatonin And Magnesium-Containing Pod","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Bettery S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Powder","sponsorNew":"Bettery S.A. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bettery S.A. \/ Inapplicable"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Vedistry Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Vedistry Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Vedistry Private Limited"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Ritual Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Ritual Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Ritual Inc."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Sleep","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Nuritas Ltd","sponsor":"RDC Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Peptisleep","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Nuritas Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuritas Ltd \/ RDC Clinical","highestDevelopmentStatusID":"1","companyTruncated":"Nuritas Ltd \/ RDC Clinical"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Hemp","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"Performance First","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Piper Methysticum Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thorne HealthTech \/ Performance First","highestDevelopmentStatusID":"1","companyTruncated":"Thorne HealthTech \/ Performance First"},{"orgOrder":0,"company":"Beam","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Beam Organics Dream","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Beam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Beam \/ Citruslabs"},{"orgOrder":0,"company":"Botanee Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Poria","moa":"Immune","graph1":"Sleep","graph2":"Undisclosed","graph3":"Botanee Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanee Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Botanee Group \/ Inapplicable"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"BioActor","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Citrus Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ BioActor","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ BioActor"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Reckitt Benckiser","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Reckitt Benckiser Group PLC","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Reckitt Benckiser Group PLC"},{"orgOrder":0,"company":"Chi-Chang Huang","sponsor":"Bened Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Limosilactobacillus Fermentum","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Chi-Chang Huang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chi-Chang Huang \/ Bened Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Chi-Chang Huang \/ Bened Biomedical"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Sleep","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Bare Performance Nutrition","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Bare Performance Supplement","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Bare Performance Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bare Performance Nutrition \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bare Performance Nutrition \/ Citruslabs"},{"orgOrder":0,"company":"University of Reading","sponsor":"Naturex","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Reading \/ Naturex","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Naturex"},{"orgOrder":0,"company":"Vedic Lifesciences Pvt. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VL-NL-02","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Vedic Lifesciences Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BLa80","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Ingredia S.A.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lactium","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Ingredia S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingredia S.A. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Ingredia S.A. \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Baycrest | University Health Network, Toronto | Centre for Addiction and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CPAP Therapy","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Baycrest | University Health Network, Toronto | Centre for Addiction and Mental Health","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Baycrest | University Health Network, Toronto | Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ORX142","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotek","sponsor":"AdSalutem Sleep Institute","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Diamino Oxidase","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Biotek \/ AdSalutem Sleep Institute","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotek \/ AdSalutem Sleep Institute"},{"orgOrder":0,"company":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"YZJ-1139","moa":"H1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Eszopiclone","moa":"GABA-A receptor; anion channel","graph1":"Sleep","graph2":"Phase IV","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"11","companyTruncated":"University of Sao Paulo \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sheffield Hallam University","sponsor":"Biotiful | University of Leeds | Nimble Science","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Kefir","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Sheffield Hallam University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheffield Hallam University \/ Biotiful | University of Leeds | Nimble Science","highestDevelopmentStatusID":"1","companyTruncated":"Sheffield Hallam University \/ Biotiful | University of Leeds | Nimble Science"},{"orgOrder":0,"company":"Huazhong University of Science and Technology","sponsor":"Wuhan Wuchang Hospital | Abinopharm Inc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Urolithin A","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Huazhong University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Huazhong University of Science and Technology \/ Wuhan Wuchang Hospital | Abinopharm Inc","highestDevelopmentStatusID":"1","companyTruncated":"Huazhong University of Science and Technology \/ Wuhan Wuchang Hospital | Abinopharm Inc"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Botanical Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Atlantia Food Clinical Trials"}]

    Find Clinical Drug Pipelines for Sleep

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orion Corporation

                            Finland
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasipimidine

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of Tasipimidine in Sleepless Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 04, 2025

                            Lead Product(s) : Tasipimidine

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Cosette Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosette Acquires Ambien® and Ambien CR® from Sanofi US

                            Details : Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

                            Product Name : Ambien

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Cosette Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Breckenridge Pharmaceutical

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Breckenridge Pharmaceutical, Inc. Announces Launch of Zolpidem Tartrate Extended-Release Tablets, USP (generic...

                            Details : Ambien-Generic (zolpidem tartrate) is a small molecule, GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. It is indicated for the treatment of insomnia.

                            Product Name : Ambien-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 07, 2021

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Breckenridge Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers W...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 02, 2018

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sleep Satisfaction and Psychomotor Performance of Adults

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2010

                            Lead Product(s) : Zolpidem Tartrate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Extension Study of ORX750 in Narcolepsy & Idiopathic Hypersomnia

                            Details : ORX750 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Narcolepsy.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX142

                            Therapeutic Area : Sleep

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa IND Cleared for ORX142 with Sleep Deprivation Data Expected This Year

                            Details : ORX142 is a novel orexin receptor 2 (OX2R) agonist, small molecule drug candidate, which is being evaluated for the treatment of neurological and neurodegenerative disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 16, 2025

                            Lead Product(s) : ORX142

                            Therapeutic Area : Sleep

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Fujian Shengdi Pharmaceutical

                            Country arrow
                            Vitafoods
                            Not Confirmed

                            Fujian Shengdi Pharmaceutical

                            Country arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HRS9531

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HRS9531 Injection Efficacy and Safety In OSA and Obese Subjects

                            Details : HRS9531 is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Sleep Apnea, Obstructive.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 16, 2025

                            Lead Product(s) : HRS9531

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jazz Pharmaceuticals

                            Ireland arrow
                            Vitafoods
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JZP441

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 07, 2025

                            Lead Product(s) : JZP441

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Jazz Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Takeda Pharmaceutical

                            Japan arrow
                            Vitafoods
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-360

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2025

                            Lead Product(s) : TAK-360

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth